Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul-Aug;16(4):15579883221115593.
doi: 10.1177/15579883221115593.

Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic

M S Rahnama'i  1   2
Affiliations

Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic

M S Rahnama'i. Am J Mens Health. 2022 Jul-Aug.

Abstract

Due to the COVID-19 pandemic, major congresses and many teaching opportunities as well as the usual visits from medical advisors of pharmaceutical firms have been postponed and canceled. The major trials of prostate cancer in the last 5 years in each state are shortly discussed providing a panoramic overview of the available evidence and data on prostate cancer treatment. Apalutamide, enzalutamide, and darolutamide have proven to have clinical benefits when added to androgen deprivation therapy for patients with nonmetastatic castration-resistant prostate cancer. In patients in the metastatic hormone-sensitive setting, next to docetaxel, abiraterone, enzalutamide, and apalutamide have been shown to significantly improve overall survival and progression-free survival in comparison to standard hormone therapy. In addition, docetaxel abiraterone and enzalutamide are widely used in the metastatic setting. For second-line therapy of metastasized prostate cancer patients who have received either docetaxel or abiraterone or enzalutamide, olaparib, cabazitaxel, radium, and lutetium therapy have been shown to be beneficial in selected patient groups.

Keywords: abiraterone; cabazitaxel; darolutamide; enzalutamide; oncology/cancer; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
An Overview of Approved Drugs for Each State of Prostate Cancer Disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. ABMS and ACGME Joint Principles: Physician Training During the COVID-2019 Accessed April 30, 2020. (2020)
    1. Agarwal N., McQuarrie K., Bjartell A., Chowdhury S., Pereira de Santana Gomes A. J., Chung B. H., Özgüroğlu M., Soto A. J., Merseburger A. S., Uemura H., Ye D., Given R., Cella D., Basch E., Miladinovic B., Dearden L., Deprince K., Naini V., Lopez-Gitlitz A., Chi K. N., & on behalf of the TITAN investigators. (2019). Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): A randomised, placebo-controlled, phase 3 study. The Lancet Oncology, 20(11), 1518–1530. 10.1016/S1470-2045(19)30620-5 - DOI - PubMed
    1. Annala M., Fu S., Bacon J. V. W., Sipola J., Iqbal N., Ferrario C., Ong M., Wadhwa D., Hotte S. J., Lo G., Tran B., Wood L. A., Gingerich J. R., North S. A., Pezaro C. J., Ruether J. D., Sridhar S. S., Kallio H. M. L., Khalaf D. J., Wong A., . . . Chi K. N. (2021). Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: A multicentre, randomised, open-label, phase II trial. Annals of Oncology, 32(7), 896–905. 10.1016/j.annonc.2021.03.205 - DOI - PubMed
    1. Armstrong A. J., Szmulewitz R. Z., Petrylak D. P., Holzbeierlein J., Villers A., Azad A., Alcaraz A., Alekseev B., Iguchi T., Shore N. D., Rosbrook B., Sugg J., Baron B., Chen L., Stenzl A. (2019). ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. Journal of Clinical Oncology, 37(32), 2974–2986. 10.1200/JCO.19.00799 - DOI - PMC - PubMed
    1. Beer T. M., Armstrong A. J., Rathkopf D. E., Loriot Y., Sternberg C. N., Higano C. S., Iversen P., Bhattacharya S., Carles J., Chowdhury S., Davis I. D., de Bono J. S., Evans C. P., Fizazi K., Joshua A. M., Kim C., Kimura G., Mainwaring P., Mansbach H., Miller K., . . . for the PREVAIL Investigators. (2014). Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine, 371(5), 424–433. 10.1056/NEJMoa1405095 - DOI - PMC - PubMed